The historical rank and industry rank for Aegerion Pharmaceuticals's Net Margin % or its related term are showing as below:
AEGR's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -162.84 * Ranked among companies with meaningful Net Margin % only.
Aegerion Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aegerion Pharmaceuticals's Net Margin %
For the Biotechnology subindustry, Aegerion Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aegerion Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aegerion Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aegerion Pharmaceuticals's Net Margin % falls into.
Aegerion Pharmaceuticals Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Aegerion Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aegerion Pharmaceuticals (NAS:AEGR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aegerion Pharmaceuticals Net Margin % Related Terms
Thank you for viewing the detailed overview of Aegerion Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Aegerion Pharmaceuticals (Aegerion Pharmaceuticals) Business Description
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AEGR has been successfully added to your 